News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. Evotec and Oxford Create Novel Partnership Called »LAB282«

Evotec and Oxford Create Novel Partnership Called »LAB282«10/11/2016- LAB282 is a joint effort by Oxford University, Oxford University Innovation Ltd, Oxford Sciences Innovation and Evotec to select and accelerate early-stage projects out of Oxford University with £ 13 m (over EUR 14 m) translational discovery fundEvotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a novel strategic partnership with the University of Oxford, Oxford University Inno


2. Prime Minister Opened £42m Biodata Innovation Centre and New Sequencin

Prime Minister Opened £42m Biodata Innovation Centre and New Sequencing Facility21/11/2016The UK Prime Minister Rt Hon Theresa May today (21 November) joined key stakeholders from across the life sciences sector to open the Wellcome Trust Sanger Institute’s new Bridget Ogilvie Building and the Biodata Innovation Centre at the Wellcome Genome Campus in Cambridge.Professor Sir Mike Stratton, Director of the Wellcome Trust Sanger Institute and Chief Executive Officer of the Wellcome Geno


3. GSK Files Regulatory Submission in US for Once-daily Closed Triple Com

GSK Files Regulatory Submission in US for Once-daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD21/11/2016GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) for patients with chronic obstructive pulmonary disease (COPD). This fo


4. GSK Announces Phase lll Study of Mepolizumab Meets Co-primary Endpoint

GSK Announces Phase lll Study of Mepolizumab Meets Co-primary Endpoints and All Secondary Endpoints in Patients with Eosinophilic Granulomatosis with Polyangiitis23/11/2016GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that both co-primary endpoints and all secondary endpoints were met in a pivotal phase III study investigating the efficacy and safety of mepolizumab, an IL-5 antagonist, in patients with relapsing and refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare di


5. GSK Starts Phase III Programme with Daprodustat for Anaemia Associated

GSK Starts Phase III Programme with Daprodustat for Anaemia Associated with Chronic Kidney Disease24/11/2016GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a phase III development programme investigating daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anaemia associated with chronic kidney disease (CKD).The phase III programme includes two studies evaluating the safety and efficacy of daprodustat compared to recombinant hu



Page 18 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2019